{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-338020","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2026-08-06T20:11:42+00:00","discovered_at":"2026-08-06T20:13:00.710960+00:00","generated_at":"2026-08-06T20:16:01.844812+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lineage Cell Therapeutics Q2 2026 net income $1.5M; cash runway to Q3 2028","bullets":["Q2 2026 net income of $1.5M ($0.01 basic EPS) vs net loss of $30.5M in Q2 2025; revenue $1.1M, down from $2.8M.","Cash $50.8M expected to fund operations into Q3 2028.","RG6501 (OpRegen) Phase 1/2a 3-year data showed sustained BCVA gains and retinal structure restoration in Cohort 4.","COR1 corneal endothelial cell therapy program advanced to in-vivo animal testing; initial data expected in 2026.","Established Scientific Advisory Board with Joachim Fruebis, PhD as founding member."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-338020","json":"https://secwatch.observer/filing/0001193125-26-338020.json","markdown":"https://secwatch.observer/filing/0001193125-26-338020.md","text":"https://secwatch.observer/filing/0001193125-26-338020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000119312526338020/0001193125-26-338020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000119312526338020/lctx-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:16:01.844812+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}